S&P 500   3,168.33 (+0.42%)
DOW   26,363.85 (+1.07%)
AAPL   383.10 (+0.31%)
MSFT   206.37 (-0.34%)
FB   237.72 (-0.54%)
GOOGL   1,504.02 (-0.54%)
NVDA   405.36 (+0.81%)
CGC   17.32 (+0.12%)
BABA   246.02 (-2.25%)
TSLA   1,529.72 (+2.18%)
AMD   53.89 (+0.56%)
T   29.92 (+0.50%)
F   6.28 (+3.46%)
DIS   118.56 (+2.00%)
NFLX   515.19 (-1.96%)
BAC   23.96 (-0.99%)
BA   176.91 (+0.72%)
S&P 500   3,168.33 (+0.42%)
DOW   26,363.85 (+1.07%)
AAPL   383.10 (+0.31%)
MSFT   206.37 (-0.34%)
FB   237.72 (-0.54%)
GOOGL   1,504.02 (-0.54%)
NVDA   405.36 (+0.81%)
CGC   17.32 (+0.12%)
BABA   246.02 (-2.25%)
TSLA   1,529.72 (+2.18%)
AMD   53.89 (+0.56%)
T   29.92 (+0.50%)
F   6.28 (+3.46%)
DIS   118.56 (+2.00%)
NFLX   515.19 (-1.96%)
BAC   23.96 (-0.99%)
BA   176.91 (+0.72%)
S&P 500   3,168.33 (+0.42%)
DOW   26,363.85 (+1.07%)
AAPL   383.10 (+0.31%)
MSFT   206.37 (-0.34%)
FB   237.72 (-0.54%)
GOOGL   1,504.02 (-0.54%)
NVDA   405.36 (+0.81%)
CGC   17.32 (+0.12%)
BABA   246.02 (-2.25%)
TSLA   1,529.72 (+2.18%)
AMD   53.89 (+0.56%)
T   29.92 (+0.50%)
F   6.28 (+3.46%)
DIS   118.56 (+2.00%)
NFLX   515.19 (-1.96%)
BAC   23.96 (-0.99%)
BA   176.91 (+0.72%)
S&P 500   3,168.33 (+0.42%)
DOW   26,363.85 (+1.07%)
AAPL   383.10 (+0.31%)
MSFT   206.37 (-0.34%)
FB   237.72 (-0.54%)
GOOGL   1,504.02 (-0.54%)
NVDA   405.36 (+0.81%)
CGC   17.32 (+0.12%)
BABA   246.02 (-2.25%)
TSLA   1,529.72 (+2.18%)
AMD   53.89 (+0.56%)
T   29.92 (+0.50%)
F   6.28 (+3.46%)
DIS   118.56 (+2.00%)
NFLX   515.19 (-1.96%)
BAC   23.96 (-0.99%)
BA   176.91 (+0.72%)
Log in

NASDAQ:YMABY-mAbs Therapeutics Stock Price, Forecast & News

$38.75
-0.08 (-0.21 %)
(As of 07/14/2020 11:37 AM ET)
Add
Compare
Today's Range
$38.10
Now: $38.75
$39.45
50-Day Range
$37.66
MA: $43.20
$49.53
52-Week Range
$14.16
Now: $38.75
$50.49
Volume3,146 shs
Average Volume256,321 shs
Market Capitalization$1.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Read More
Y-mAbs Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-81,030,000.00

Miscellaneous

Employees32
Market Cap$1.54 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

How has Y-mAbs Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, YMAB shares have increased by 68.6% and is now trading at $38.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Y-mAbs Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Y-mAbs Therapeutics.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Y-mAbs Therapeutics.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) released its earnings results on Thursday, May, 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.04. View Y-mAbs Therapeutics' earnings history.

What price target have analysts set for YMAB?

8 brokers have issued 12-month target prices for Y-mAbs Therapeutics' stock. Their forecasts range from $39.00 to $52.00. On average, they anticipate Y-mAbs Therapeutics' stock price to reach $44.60 in the next year. This suggests a possible upside of 15.1% from the stock's current price. View analysts' price targets for Y-mAbs Therapeutics.

Has Y-mAbs Therapeutics been receiving favorable news coverage?

News coverage about YMAB stock has trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Y-mAbs Therapeutics earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Y-mAbs Therapeutics.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
  • Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $38.75.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.54 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.